Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Peripheral Artery Disease IV: Nursing Management

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.

PLoS computational biology·2026

Same author

Improving the Severity Classification System of Diabetes-Related Foot Infections: Necrosis is a Better Predictor of Amputation Than Systemic Inflammatory Response.

Foot & ankle specialist·2026

Same author

Metabolic and Microvascular Risk Factors Associated With Brain Health in Type 1 Diabetes.

Annals of clinical and translational neurology·2026

Same author

From Glucose to Limb Salvage: New Therapeutic Frontiers to Redefine Outcomes in Diabetic Foot Disease.

Diabetes care·2026

Same author

Do Immediate Perioperative Glucose Measurements Predict Outcomes in Non-Elective Pedal Amputation?

Foot & ankle specialist·2026

Same author

Response to comments on Pop-Busui et al. Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure. Diabetes Care 2025;48:2145-2153.

Diabetes care·2026

Search research articles

Related Experiment Video

Updated: Aug 29, 2025

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

The NIDDK Diabetic Foot Consortium.

Teresa L Z Jones¹, Crystal M Holmes², Aimee Katona²

¹National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.

Journal of Diabetes Science and Technology

|September 5, 2022

Summary

This summary is machine-generated.

The Diabetic Foot Consortium (DFC) aims to improve diabetic foot ulcer (DFU) healing and prevent amputations by developing biomarkers and a research platform. This initiative focuses on robust data collection and analysis to advance clinical care and research for DFU patients.

Keywords:

biomarkers clinical network diabetic foot ulcers diabetic wound healing

More Related Videos

High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model

High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model

Published on: March 16, 2022

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

Published on: January 3, 2011

Related Experiment Videos

Last Updated: Aug 29, 2025

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model

High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model

Published on: March 16, 2022

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

Corneal Confocal Microscopy: A Novel Non-invasive Technique to Quantify Small Fibre Pathology in Peripheral Neuropathies

Published on: January 3, 2011

Area of Science:

Diabetology
Wound Healing Research
Biomarker Discovery

Background:

Diabetic foot ulcers (DFUs) represent a significant complication of diabetes, often leading to amputations.
High-quality clinical research is needed to improve DFU healing and prevention strategies.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the Diabetic Foot Consortium (DFC) in 2018 to address these needs.

Purpose of the Study:

To establish a collaborative organization for high-quality clinical research on DFUs.
To develop and validate biomarkers for DFU clinical care and research.
To create a platform for scientifically sound clinical trial design and analysis of DFU risk factors.

Main Methods:

The DFC operates with a Data Coordinating Center (DCC), clinical sites, and Biomarker Analysis Units (BAUs).
A platform approach captures comprehensive data (clinical history, outcomes, imaging, biologic measurements) from a large patient cohort.
Biosamples are collected for a biorepository to support future research.

Main Results:

The DFC is actively studying biomarkers to predict wound healing and recurrence.
A computational-based DFU risk factor profile is being developed from longitudinal data.
The consortium is implementing strategies to overcome recruitment and eligibility challenges in DFU trials.

Conclusions:

The DFC is building a robust infrastructure to advance DFU research and clinical practice.
The initiative aims to significantly improve outcomes for patients with diabetic foot ulcers.
Future research will incorporate social determinants of health and expand stakeholder partnerships.